TATVA CHIN PHARM CHEM LTD

Tatva Chintan Pharma Chem Limited held its Q1 FY27 earnings conference call on July 17, 2026, where management reported significant financial growth. The company achieved operating revenue of INR 1,671 million, marking a 43% year-on-year increase and a 25% sequential rise. EBITDA reached INR 323 million, reflecting an 86% year-on-year growth. Segment-wise, Phase Transfer Catalysts generated INR 428 million in revenue, while Electrolyte Salts saw a decline of 52% sequentially but a 76% year-on-year increase. Management highlighted the positive developments across multiple business segments and announced plans for a new greenfield manufacturing facility with an investment of approximately INR 200 crores. The management expressed confidence in the company's growth trajectory, citing increased customer demand and the successful qualification of products in the semiconductor sector. The call concluded with management thanking stakeholders for their support and emphasizing the company's commitment to innovation and growth.

Management emphasized strong financial performance and growth opportunities across various segments.